Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) issued its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.27. The medical equipment provider had revenue of $85.70 million for the quarter, compared to the consensus estimate of $88.72 million. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. Lantheus's revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.25 earnings per share. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Lantheus.

Lantheus updated its FY19 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $1.09-1.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.12. The company issued revenue guidance of $346-350 million, compared to the consensus revenue estimate of $360.07 million.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

News stories about LNTH stock have trended negative on Sunday, InfoTrie reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Lantheus.

Lantheus saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,410,000 shares, an increase of 6.8% from the August 30th total of 1,320,000 shares. Based on an average daily volume of 432,500 shares, the short-interest ratio is presently 3.3 days. Currently, 3.7% of the company's stock are sold short. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Heska (HSKA), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Vermillion (VRML), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB) and GeneNews (GNWSF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Ares Capital (ARCC), Cypress Semiconductor (CY), Endocyte (ECYT), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD) and Anavex Life Sciences (AVXL).

(LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

LNTH stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $18.99.

Lantheus has a market capitalization of $737.19 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]